QuidelOrtho (NASDAQ:QDEL) Issues Quarterly Earnings Results

QuidelOrtho (NASDAQ:QDEL) issued its quarterly earnings results on Tuesday. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.13, FiscalAI reports. QuidelOrtho had a positive return on equity of 3.20% and a negative net margin of 14.24%. The business had revenue of $618.90 million during the quarter, compared to the consensus estimate of $627.83 million. During the same quarter last year, the company earned $0.80 earnings per share. The company’s quarterly revenue was down 11.6% on a year-over-year basis.

Here are the key takeaways from QuidelOrtho’s conference call:

• China and respiratory weakness drove the decline: Q3 revenue fell 12% to $619 million, with China down 45% and Point of Care down 27% as respiratory revenue declined 39%. Management expects China to fall from about 8% of revenue in 2026 to 4%–5% in 2027 amid destocking, pricing pressure, and competition.
• Core businesses continued to grow outside China: Labs revenue rose 4% and immunohematology revenue rose 3%, supported by demand across key markets and the company’s installed base.
• A new restructuring program targets more than $80 million in annual savings in 2027, which management says should more than offset near-term China headwinds. The program will incur $30 million–$35 million in restructuring charges, with most of the cash outflow expected in Q4 2026.
• Guidance and leverage reflect continued pressure: The company narrowed 2026 revenue guidance to $2.52 billion–$2.54 billion and expects adjusted EBITDA of $540 million–$545 million and adjusted EPS of $0.65–$0.70. Free cash flow was approximately break-even in Q3, while net leverage rose to 4.5x from 4.3x in Q2.

QuidelOrtho Stock Up 1.8%

Shares of QDEL stock opened at $14.35 on Thursday. The stock’s 50-day simple moving average is $12.72 and its 200-day simple moving average is $16.17. The company has a debt-to-equity ratio of 1.43, a quick ratio of 0.76 and a current ratio of 1.39. The firm has a market capitalization of $983.98 million, a PE ratio of 16.38 and a beta of 0.77. QuidelOrtho has a fifty-two week low of $9.92 and a fifty-two week high of $35.58.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on QDEL shares. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Friday, October 9th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Thursday, October 15th. Finally, Citigroup raised their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $13.62.

More QuidelOrtho News

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: QuidelOrtho reported adjusted earnings of $0.31 per share, above the $0.18 analyst estimate. QuidelOrtho Q3 earnings
• Positive Sentiment: The company’s cost-transformation and restructuring program is expected to generate more than $80 million in annual savings in 2027, potentially supporting future profitability. Third-quarter financial results
• Positive Sentiment: Management highlighted growth in Labs and Immunohematology businesses outside China, pointing to areas of underlying strength. Third-quarter financial results
• Neutral Sentiment: QuidelOrtho narrowed its full-year 2026 guidance ranges. The update provides a tighter outlook, but the available reports do not specify whether the change raises or lowers expectations. 2026 earnings guidance
• Negative Sentiment: Revenue was $618.9 million, below the cited $627.8 million consensus and down 11.6% year over year. EPS also fell from $0.80 a year earlier. The weak top line and year-over-year earnings decline likely overshadowed the quarterly EPS beat. Third-quarter earnings results

About QuidelOrtho

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.